432 related articles for article (PubMed ID: 36755812)
1. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy.
Palanivelu L; Liu CH; Lin LT
Front Immunol; 2022; 13():1038226. PubMed ID: 36755812
[TBL] [Abstract][Full Text] [Related]
2. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.
Guo ZS; Liu Z; Bartlett DL
Front Oncol; 2014; 4():74. PubMed ID: 24782985
[TBL] [Abstract][Full Text] [Related]
4. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1
Kalus P; De Munck J; Vanbellingen S; Carreer L; Laeremans T; Broos K; Dufait I; Schwarze JK; Van Riet I; Neyns B; Breckpot K; Aerts JL
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563257
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
7. Investigating the potential of oncolytic viruses for cancer treatment via MSC delivery.
Ghaleh HEG; Vakilzadeh G; Zahiri A; Farzanehpour M
Cell Commun Signal; 2023 Sep; 21(1):228. PubMed ID: 37667271
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses as therapeutic cancer vaccines.
Bartlett DL; Liu Z; Sathaiah M; Ravindranathan R; Guo Z; He Y; Guo ZS
Mol Cancer; 2013 Sep; 12(1):103. PubMed ID: 24020520
[TBL] [Abstract][Full Text] [Related]
9. High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment.
Ma J; Zhang C; Shi G; Yue D; Shu Y; Hu S; Qi Z; Chen Y; Zhang B; Zhang Y; Huang A; Su C; Zhang Y; Deng H; Cheng P
Mol Ther; 2022 Feb; 30(2):644-661. PubMed ID: 34547462
[TBL] [Abstract][Full Text] [Related]
10. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.
Mardi A; Shirokova AV; Mohammed RN; Keshavarz A; Zekiy AO; Thangavelu L; Mohamad TAM; Marofi F; Shomali N; Zamani A; Akbari M
Cancer Cell Int; 2022 Apr; 22(1):168. PubMed ID: 35488303
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response.
Wu YY; Sun TK; Chen MS; Munir M; Liu HJ
Front Cell Infect Microbiol; 2023; 13():1142172. PubMed ID: 37009515
[TBL] [Abstract][Full Text] [Related]
12. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy.
Kaur SD; Singh AD; Kapoor DN
Med Oncol; 2023 Jun; 40(7):205. PubMed ID: 37318642
[TBL] [Abstract][Full Text] [Related]
15. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
16. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
17. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
18. Application of oncolytic virus in tumor therapy.
Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
[TBL] [Abstract][Full Text] [Related]
19. Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer.
Zahedi-Amiri A; Malone K; Beug ST; Alain T; Yeganeh B
Cells; 2021 Oct; 10(10):. PubMed ID: 34685652
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.
Calvillo-Rodríguez KM; Lorenzo-Anota HY; Rodríguez-Padilla C; Martínez-Torres AC; Scott-Algara D
Front Immunol; 2023; 14():1294434. PubMed ID: 38077402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
